Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 9/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778865 | 0.85 | TACR2 (0.55) | DRD2SLC6A4CCR5TACR2OPRM1 | |
| SCHEMBL5858616 | 0.80 | DRD2 (0.69) | DRD2SLC6A4CCR5TACR2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6777403 | 0.74 | TACR2 (0.56) | DRD2SLC6A4CCR5TACR2CYP2D6 | |
| SCHEMBL3746308 | 0.73 | DRD2 (0.62) | DRD2SLC6A4CCR5TACR2PKM | |
| SCHEMBL3754922 | 0.73 | DRD2 (0.65) | DRD2SLC6A4CCR5TACR2PKM | |
| SCHEMBL5858744 | 0.73 | DRD2 (0.68) | DRD2SLC6A4CCR5TACR2CYP2D6 | |
| SCHEMBL3752313 | 0.72 | DRD2 (0.61) | DRD2SLC6A4CCR5TACR2PKM | |
| SCHEMBL6780052 | 0.72 | CCR5 (0.62) | CCR5CYP2D6FPR2OPRM1OPRK1 | |
| SCHEMBL6780430 | 0.71 | CCR5 (0.49) | CCR5CYP2D6OPRM1OPRK1 | |
| SCHEMBL904830 | 0.70 | DRD2 (0.60) | DRD2SLC6A4CCR5TACR2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790854-B2 | TREATMENT OF DEPRESSION, EPILEPSY AND PARKINSON'S ISEASE, ANALGESICS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030176693-A1 | Diphenylalkylamine derivatives useful as opioid receptor agonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1277737-A1 | DIPHENYLALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176693-A1 | Diphenylalkylamine derivatives useful as opioid receptor agonists | OPRM1, OPRK1, OPRL1 | DRD2 95/4885SLC6A4 754/4885CCR5 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.